Patent · US Active

Coagulation factor X polypeptides with modified activation properties

US9347051B2 · kind B2 · utility

5Cited by

5References

4Claims

0Family size

Assignee

CSL Behring AG · DE

Inventors

Stefan Schulte · Marburg, DE
Hans-Peter Hauser · Marburg, DE
Uwe Kalina · Marburg, DE
Thomas Weimer · Gladenbach, DE

Key dates

Filing date	Feb 19, 2007
Grant date	May 24, 2016
Priority date	—
Expiry date	Apr 20, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y304/21006
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to modified cDNA sequences coding for factor X polypeptides, in particular human factor X and its derivatives which can bypass the need for either factor VIIIa/factor IXa or factor VIIa/tissue factor for activation. The invention relates further to recombinant expression vectors containing such modified cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having altered activation properties, and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.